These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 4669737

  • 1. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M, Vardi J, Kesten M.
    Harefuah; 1972 Nov 01; 83(9):362-4. PubMed ID: 4669737
    [No Abstract] [Full Text] [Related]

  • 2. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W, Linauer W, Mentasti M, Riederer P.
    Wien Med Wochenschr; 1974 Jun 01; 124(22):340-4. PubMed ID: 4275492
    [No Abstract] [Full Text] [Related]

  • 3. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E, Cerillo A, Tata MR, Decina A.
    Acta Neurol (Napoli); 1973 Jun 01; 28(2):208-12. PubMed ID: 4709076
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L, de la Garza R, Ivan-Reynoso G.
    Arch Invest Med (Mex); 1974 Jun 01; 5(2):105-16. PubMed ID: 4433198
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H.
    Wien Med Wochenschr; 1973 Jun 30; 123(26):433-5. PubMed ID: 4578743
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B, Steinhäusl H.
    Wien Med Wochenschr; 1972 Jun 17; 122(25):369-71. PubMed ID: 4558132
    [No Abstract] [Full Text] [Related]

  • 9. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A, Vielhaber K.
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct 17; 40(10):564-8. PubMed ID: 4565521
    [No Abstract] [Full Text] [Related]

  • 10. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W, Eisenlohr JJ.
    Nervenarzt; 1974 Jan 17; 45(2):22-9. PubMed ID: 4601993
    [No Abstract] [Full Text] [Related]

  • 11. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J, Kase JC, Mena I, Palacios E.
    Rev Med Chil; 1973 Jun 17; 101(6):452-5. PubMed ID: 4764560
    [No Abstract] [Full Text] [Related]

  • 12. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
    Völler GW, Muschard F.
    Med Welt; 1973 Apr 27; 24(17):705-7. PubMed ID: 4750934
    [No Abstract] [Full Text] [Related]

  • 13. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, de Ajuriaguerra J.
    Nouv Presse Med; 1973 Feb 03; 2(5):315-6. PubMed ID: 4686226
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M, Barba C, Ruggieri S, Zamponi A, Agnoli A.
    Riv Neurol; 1974 Feb 03; 44(5):303-30. PubMed ID: 4217465
    [No Abstract] [Full Text] [Related]

  • 16. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G, Pennetta R.
    Acta Neurol (Napoli); 1974 Feb 03; 29(3):252-63. PubMed ID: 4417098
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bensarazid with L-dopa in the treatment of parkinson's disease.
    Van Wieringen A.
    S Afr Med J; 1974 Feb 09; 48(6):206-9. PubMed ID: 4814495
    [No Abstract] [Full Text] [Related]

  • 19. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ, Somerville B.
    Med J Aust; 1974 Mar 23; 1(12):429-32. PubMed ID: 4598384
    [No Abstract] [Full Text] [Related]

  • 20. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS, Hsu TH, Bianchine JR.
    J Clin Invest; 1972 Feb 23; 51(2):452-5. PubMed ID: 5009125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.